PDCD1 and non-small cell lung carcinoma: These encouraging results have led to the opening of three Phase Ib/II clinical trials combining anti-RANKL denosumab with anti-PD-1 nivolumab alone or with anti-CTLA-4 ipililumab (in NSCLC and renal cancers) (Table 6), whose results are awaited.